{"id":40885,"date":"2020-11-01T22:55:00","date_gmt":"2020-11-01T14:55:00","guid":{"rendered":"https:\/\/www.chinapulse.com\/?p=127448"},"modified":"2020-11-01T22:55:00","modified_gmt":"2020-11-01T14:55:00","slug":"one-more-chinese-covid-19-vaccine-ready-for-phase-3-clinical-trials","status":"publish","type":"post","link":"https:\/\/www.chinalegalblog.com\/en\/2020\/11\/01\/one-more-chinese-covid-19-vaccine-ready-for-phase-3-clinical-trials\/","title":{"rendered":"One more Chinese COVID-19 vaccine ready for phase-3 clinical trials"},"content":{"rendered":"<p>BEIJING &#8212; A COVID-19 vaccine candidate developed by the Institute of Microbiology under the Chinese Academy of Sciences has shown to be safe in early-stage trials, suggesting potential for further clinical tests.<\/p>\n<p>The results of phase-1 and phase-2 trials support the safety and immunogenicity of this recombinant subunit vaccine in healthy participants, and no serious adverse events have been found so far, the institute said in a statement on Friday.&#8230;<\/p>\n<p>This news comes via <a href=\"https:\/\/www.chinapulse.com\/\"  title=\"Best source for Chinese news in English\">ChinaPulse.com, which delivers news, data, analysis, and insights on Chinese business, travel, finance, health, military, investment, and technology<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>BEIJING &#8212; A COVID-19 vaccine candidate developed by the Institute of Microbiology under the Chinese Academy of Sciences has shown to be safe in early-stage trials, suggesting potential for further clinical tests.<br \/>\nThe results of phase-1 and phase-&#8230;<\/p>\n","protected":false},"author":250,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[65,213,929,194,1542],"tags":[3472,1935,10324,7035],"class_list":["post-40885","post","type-post","status-publish","format-standard","hentry","category-beijing","category-china-news","category-hunan","category-news-chinese-law","category-technology","tag-chinese","tag-chongqing","tag-covid-19","tag-vaccine"],"_links":{"self":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/40885"}],"collection":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/users\/250"}],"replies":[{"embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/comments?post=40885"}],"version-history":[{"count":1,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/40885\/revisions"}],"predecessor-version":[{"id":40886,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/posts\/40885\/revisions\/40886"}],"wp:attachment":[{"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/media?parent=40885"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/categories?post=40885"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.chinalegalblog.com\/en\/wp-json\/wp\/v2\/tags?post=40885"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}